S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)

Inclusion Criteria: * Patients must have a current diagnosis of breast cancer, non-small cell lung cancer, or colorectal cancer; the current diagnosis may be an initial diagnosis or recurrence and/or progression of previously diagnosed disease; cancer may be metastatic or non-metastatic * Patients must be registered prior to or on the same day as their first cycle of chemotherapy for their current disease and stage 9or disease setting). * Patients must not have had any systemic therapy (chemotherapy or combination regimens) in the 180 days just prior to registration. Prior biologic therapy, immunotherapy, tyrosine kinase inhibitors, and hormonal therapy are allowed. * Patients must be planning to receive one of the study-allowed regimens as their initial treatment for their current disease; myelosuppressive therapy must follow the standard regimen, although a dose reduction of up to 10% is permitted. This treatment may be neoadjuvant or adjuvant chemotherapy. * Patients must not be receiving or planning to receive concurrent radiation during systemic treatment. * Patients must not have any known contraindication to CSFs prior to registration, including prior hypersensitivity to Escherichia coli-derived proteins, filgrastim, pegfilgrastim, or tbo-filgrastim * Patients must be able to understand and provide information for the patient-completed study forms in either English or Spanish * Patients may have had a prior malignancy * Patients must not be participating or plan to pa…